Lapatinib, a dual inhibitor of EGFR and ErbB2 tyrosine kinases, induced autophagic cell death in ErbB2 overexpressing breast cancer cells [76], human hepatoma cells [77], and acute myeloblastic leukemia [78]. Here, EGFR is linked to breast carcinoma.